4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-25-000012
SVP, GEN COUNSEL & CORP SEC sold 5,000 shares at an average $90.07 ($450,369)
- SVP, GEN COUNSEL & CORP SEC acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Option exercise 10b5-1 | +5,000 | $21.41 | $107,050 | 33,222 | D: show line 1 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Sale 10b5-1 | −571 | $87.77 | $50,115 | 32,651 | D: show line 2 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Sale 10b5-1 | −635 | $89.09 | $56,571 | 32,016 | D: show line 3 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Sale 10b5-1 | −1,755 | $89.95 | $157,860 | 30,261 | D: show line 4 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Sale 10b5-1 | −1,784 | $91.05 | $162,437 | 28,477 | D: show line 5 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Sale 10b5-1 | −255 | $91.71 | $23,386 | 28,222 | D: show line 6 in the form |
| Open-market sales · 5,000 sh · avg $90.07 · $450,369 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-02-05 | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 149,497 | D: show line 7 in the form |
Loading xslF345X05/wk-form4_1738962245.xml…